Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Vir Biotechnology Inc (NQ: VIR ) 9.730 -0.630 (-6.08%) Streaming Delayed Price Updated: 11:10 AM EDT, Jun 14, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 558,811 Open 10.13 Bid (Size) 9.720 (1) Ask (Size) 9.740 (1) Prev. Close 10.36 Today's Range 9.710 - 10.27 52wk Range 7.610 - 26.74 Shares Outstanding 133,976,538 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Why Is Infectious Disease-Focused Vir Biotechnology Stock Trading Higher On Wednesday? June 05, 2024 Vir Biotechnology reports promising Phase 2 SOLSTICE hepatitis delta trial results, showing high virologic response and ALT normalization rates with tobevibart and elebsiran. Via Benzinga Why Lands' End Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session June 05, 2024 Via Benzinga Performance YTD -7.42% -7.42% 1 Month -3.47% -3.47% 3 Month -7.51% -7.51% 6 Month -3.09% -3.09% 1 Year -62.61% -62.61% More News Read More Ollie's Bargain Outlet Posts Upbeat Earnings, Joins Verint Systems, Guidewire Software And Other Big Stocks Moving Higher On Wednesday June 05, 2024 Via Benzinga Evaluating Vir Biotechnology: Insights From 5 Financial Analysts May 24, 2024 Via Benzinga Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of Treatment June 05, 2024 From Vir Biotechnology, Inc. Via Business Wire Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference May 29, 2024 From Vir Biotechnology, Inc. Via Business Wire Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer May 29, 2024 From Vir Biotechnology, Inc. Via Business Wire Deep Dive Into Vir Biotechnology Stock: Analyst Perspectives (6 Ratings) May 07, 2024 Via Benzinga Assessing Vir Biotechnology: Insights From 5 Financial Analysts March 15, 2024 Via Benzinga Recap: Vir Biotechnology Q4 Earnings February 22, 2024 Via Benzinga Vir Biotechnology to Host 2024 Annual Meeting of Stockholders May 23, 2024 From Vir Biotechnology, Inc. Via Business Wire Multiple Abstracts Highlighting Vir Biotechnology’s Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024 May 22, 2024 From Vir Biotechnology, Inc. Via Business Wire Vir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024 May 21, 2024 From Vir Biotechnology, Inc. Via Business Wire VIR Stock Earnings: Vir Biotechnology Beats EPS for Q1 2024 May 02, 2024 Via InvestorPlace Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results May 02, 2024 From Vir Biotechnology, Inc. Via Business Wire Vir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024 April 30, 2024 From Vir Biotechnology, Inc. Via Business Wire Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors April 18, 2024 From Vir Biotechnology, Inc. Via Business Wire Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024 April 11, 2024 From Vir Biotechnology, Inc. Via Business Wire From Six Figures to Seven: 3 Biotech Stocks Set to Make Millionaires March 19, 2024 Via InvestorPlace Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio March 13, 2024 Via InvestorPlace Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule March 05, 2024 From Vir Biotechnology, Inc. Via Business Wire 3 Highly Rated Biotech Stocks to Buy for 300% Gains February 26, 2024 Via InvestorPlace Why MercadoLibre Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session February 23, 2024 Via Benzinga Carvana Posts Q4 Results, Joins LegalZoom.com, Comfort Systems And Other Big Stocks Moving Higher On Friday February 23, 2024 Via Benzinga Topics Stocks Exposures US Equities Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences February 23, 2024 From Vir Biotechnology, Inc. Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
